Avid Bioservices (Avid Bioservices) Cash-to-Debt : 0.16 (As of Jan. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avid Bioservices's cash to debt ratio for the quarter that ended in Jan. 2024 was 0.16.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Avid Bioservices couldn't pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Avid Bioservices's Cash-to-Debt or its related term are showing as below:

CDMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 325.01 Max: No Debt
Current: 0.16

During the past 13 years, Avid Bioservices's highest Cash to Debt Ratio was No Debt. The lowest was 0.13. And the median was 325.01.

CDMO's Cash-to-Debt is ranked worse than
92.66% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs CDMO: 0.16

Avid Bioservices Cash-to-Debt Historical Data

The historical data trend for Avid Bioservices's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avid Bioservices Cash-to-Debt Chart

Avid Bioservices Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.35

1.44

0.69

0.20

Avid Bioservices Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															0.33	0.20	0.13	0.16	0.16

Competitive Comparison of Avid Bioservices's Cash-to-Debt

For the Biotechnology subindustry, Avid Bioservices's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avid Bioservices's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avid Bioservices's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Avid Bioservices's Cash-to-Debt falls into.

Avid Bioservices Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Avid Bioservices's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	38.542	/	(1.358	+	187.875)
	=	0.20

Avid Bioservices's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	30.708	/	(142.731	+	52.17)
	=	0.16

Avid Bioservices (NAS:CDMO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Avid Bioservices Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices (Avid Bioservices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

TEHN:Germany

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Executives

Matthew R. Kwietniak	officer: Chief Commercial Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri	officer: Chief Operations Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart	officer: Chief Financial Officer	2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell	officer: V.P., General Counsel	14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone	director	3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green	director, officer: President & CEO	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen	director
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth	director	500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg	officer: Principal Fin. & Acct. Officer	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780